AKT activation has been reported in 51% of NSCLC patient samples and 74% of NSCLC cell lines, suggesting that combining EGFR and AKT inhibition may increase anti-tumor activity and prevent the occurrence of resistance to EGFR TKIs [31, 32]. This evidence concerns the gene EGFR and neoplasm.